Physician profile
Rajeev Narayan
NPI 1093805863
$57,025.77
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $481 · 2021: $12K · 2022: $1,225 · 2023: $3,290 · 2024: $4,092 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Acquisitions: $2,899 · Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,600.00 |
| Acquisitions | $2,899.43 |
| Food and Beverage | $1,723.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24,978.00 | 2019 | |
| Medtronic, INC. | $15,885.02 | 2021-2025 | Ellipsys Vascular Access System, Corevalve Evolut R |
| Merit Medical Systems INC | $13,600.00 | 2024-2025 | Peritoneal Dialysis Systems, Wrapsody Stent Graft |
| Avenu Medical INC. | $418.38 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $255.85 | 2019-2025 | Rayaldee |
| Amgen INC. | $190.13 | 2022-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $175.20 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $162.90 | 2021-2024 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $148.63 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $126.25 | 2024-2025 | |
| Nxstage Medical, INC. | $124.45 | 2023 | Nxstage System One |
| Horizon Therapeutics Plc | $110.66 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $105.41 | 2019-2020 | |
| Medtronic Vascular, INC. | $93.73 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $91.06 | 2019-2024 | Farxiga, Lokelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $85.25 | 2023-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $81.14 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $68.68 | 2024-2025 | |
| Cormedix INC. | $44.72 | 2024 | Defencath |
| Bard Peripheral Vascular, INC. | $42.73 | 2019-2021 | |
| Travere Therapeutics, INC. | $41.99 | 2024-2025 | |
| Akebia Therapeutics INC | $40.71 | 2024-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $40.04 | 2019 | |
| Shield Therapeutics INC | $37.38 | 2022-2023 | Accrufer |
| Aurinia Pharma U.S., INC. | $26.97 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $19.86 | 2025 | Benlysta |
| Scpharmaceuticals INC. | $17.48 | 2025 | |
| W. L. Gore & Associates, INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.